Search results
7 lip 2021 · First, studies of the lifetime costs of HIV treatment should provide more details on major cost components to allow for comparisons across studies. We commend the authors’ attempt to present these details in their supplementary table.
16 wrz 2014 · Thirty-two of the 76 cost estimates report patient ages (average age: 31.78 years), and 40 provide information on distribution by sex (78% males). In 28 of the 76 cost estimates (36.84%), the primary means of transmission was intravenous-drug use, while in 36.84% of the cases, the disease was transmitted sexually.
1 lip 2021 · The median lifetime costs for managing HIV differed according to: country income level: $5221 [interquartile range (IQR)]: 2978–11 177) for low-income to $377 820 (IQR: 260 176–541 430) for high-income; study perspective: $189 230 (IQR: 14 794–424 069) for healthcare provider, to $508 804 (IQR: 174 781–812 418) for societal; and ...
We conducted meta-regression analyses of all published ICERs in the cost-effectiveness registries for 25 interventions for HIV/AIDS, malaria, syphilis, and tuberculosis, including evidence from high-income countries as well as low-income and middle-income countries.
30 cze 2023 · Modelling results predicted that the linkage-to-care goal increased life expectancy by 0.4 years and delayed the onset of AIDS by 1.2 years on average for every HIV-diagnosed person. Increasing early linkage-to-care costs an extra $78,195 per QALY gained, considering only benefits to index person . Early linkage-to-care and treatment initiation ...
20 mar 2021 · The list price for Truvada (emtricitabine and tenofovir disoproxil fumarate) and Descovy (emtricitabine and tenofovir alafenamide fumarate) for PrEP are approximately $22 000 (WAC) per person annually, and ART regimens for most people with HIV range from $23 000 to $39 000 (WAC) per person per year. 19 Additionally, with manufacturers assuming ...
16 mar 2022 · Currently, the lifetime treatment cost of an HIV infection is estimated at $379,668 (in 2010 dollars), therefore a prevention intervention is deemed cost-saving if its CE ratio is less than $379,668 per infection averted.
